[1] Chinese Society of Hematology, Chinese Medical Association.Expert consensus on diagnosis and treatment of myelodysplastic syndrome(2014)[J]. Chinese Journal of Hematology(中华血液学杂志), 2014, 11(35): 1024-1048. [2] Canaani J, Nagler A.Established and emerging targeted therapies in the myelodysplastic syndromes[J]. Expert Rev Hematol, 2016, 9(10): 997-1005. [3] Ades L, Itzykson R, Fenaux P.Myelodysplastic syndromes[J]. Lancet, 2014, 383(9936): 2239-2252. [4] Hu RH, Sun WL, Zhao H, et al.Clinical analysis of low-dose decitabine combined with CAG regimen in treatment of elderly patients with acute myeloid leukemia and myelodysplastic syndromes patients with intermediate- or high-risk[J]. Journal of Leukemia and Lymphoma(白血病·淋巴瘤), 2017, 26(3): 166-169. [5] Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009, 114(5): 937-951. [6] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. [7] Greenberg PL, Tuechler H, Schanz J, et al.Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12): 2454-2465. [8] Cheson BD.Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2): 419-425. [9] Chang BQ,Sun WL.Progress of hypomethylating agents in treatment of myelodysplastic syndromes[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(9): 560-563. [10] Momparler RL.Pharmacology of 5-Aza-2'-deoxycytidine (decitabine)[J]. Seminars in Hematology, 2005, 42(3 Suppl 2): S9-S16. [11] Mund C, Hackanson B, Stresemann C, et al.Characterization of DNA demethylation effects induced by 5-aza-2'-deoxycytidine in patients with myelodysplastic syndrome[J]. Cancer Research, 2005, 65(16): 7086-7090. [12] Kantarjian H, Oki Y, Garcia-Manero G, et al.Results of a rando-mized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1): 52-57. [13] Wang P.Analysis of ultra low dose decitabine cmbined with CAG regimen in the treatment of high-risk myelodysplastic syndrome and abnormal synthesis of refractory leukemia effect[J]. China Continuing Medical Education(中国继续医学教育), 2016, 8(5): 146-147. [14] Li J, Yao W, Zhou WW, et al.Clinical significance of low dose demethylation treatment of myelodysplastic syndrome[J]. Journal of Huaihai Medicine(淮海医药), 2014, 32(1): 3-5. [15] Li H, Wang L, Wu Y, et al.Very-low-dose decitabine is effective in treating intermediate- or high-risk myelodysplastic syndrome[J]. Acta Haematologica, 2017, 138(3): 168-174. [16] Liang L, Wu GC, Nie LR, et al.Efficacy of low dose decitabine combined with CAG regimen in the treatment of high-risk myelodysplastic syndrome and refractory leukemia[J]. Chinese Journal of Gerontology(中国老年学杂志), 2015, 35(8): 2073-2075. |